MONTREAL, Oct. 10 /CNW/ - ConjuChem Biotechnologies Inc. (TSX:CJB)
announced today that it has received, from the U.S. Patent & Trademark Office,
the Order Granting ConjuChem's July 9, 2007 Request for Inter Partes
Reexamination of U.S. Patent No. 6,924,264 ("The Order"). The patent, entitled
"Modified Exendins and Exendin Agonists", was issued in August 2005 and is
assigned to Amylin Pharmaceuticals, Inc.
In the Order, the U.S. Patent & Trademark Office states that a
substantial new question of patentability is raised with regard to all 21
claims in U.S. Patent No. 6,924,264 for which ConjuChem has requested
reexamination and further states that an office action on the merits will be
issued in due course.
"We are very pleased by the response of the U.S. Patent & Trademark
Office and that this process is progressing well," said Jean Silveri, Vice
President & General Counsel of Conjuchem. "We believe this reexamination
process will be especially helpful in bringing further clarity to this
particular patent area."
ConjuChem has a number of issued patents in the insulinotropic peptide
field including a composition of matter patent for PC-DAC(TM):Exendin-4
(Patent No. 6,593,295) which was issued by the U.S. Patent & Trademark Office
in July 2003. The reexamination request to the U.S. Patent & Trademark Office
does not involve any of ConjuChem's patents.
PC-DAC(TM):Exendin-4 is a therapy being developed for Type II diabetes.
Exendin-4, like Glucagon-like peptide-1 (GLP-1), is an insulinotropic peptide
and an agonist for the GLP-1 receptor. Exendin-4 decreases glucagon and
increases insulin secretion in a glucose-dependent manner. Exendin-4 may
stimulate ss-cell proliferation, restore ss-cell sensitivity to glucose, delay
gastric emptying, and increase peripheral sensitivity to glucose. The clinical
utility of Exendin-4 is somewhat limited by its relatively short half-life in
plasma. Developed with ConjuChem's proprietary PC-DAC(TM) technology,
PC-DAC(TM):Exendin-4 is a modified Exendin-4 analogue that is covalently bound
to recombinant human albumin (Recombumin(R), provided by Novozymes Delta
Limited). Data from Phase I/II clinical studies have demonstrated that this
preformed albumin-peptide conjugate has a much longer half-life than the
peptide alone. The product is a highly soluble liquid formulation that is
injectable in a small volume with a small gauge needle.
ConjuChem, developer of next generation medicines from therapeutic
peptides, is creating long-acting compounds based on bioconjugation platform
technologies. When applied to peptides, the Company's systemic DACTM and
PC-DAC(TM) Technologies enable the creation of new drugs with significantly
enhanced therapeutic properties as compared to the original peptide.
Detailed descriptions of the Company can be viewed on the Company's
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause ConjuChem's actual results, performance or achievements
to be materially different from those expressed or implied by any of the
Company's statements. Actual events or results may differ materially. We
disclaim any intention, and assume no obligation, to update these
For further information:
For further information: Lennie Ryer, CA, Vice President, Finance & CFO,
ConjuChem Biotechnologies Inc., (514) 844-5558 ext 224, email@example.com;
Mark Perrin, President & CEO, ConjuChem Biotechnologies Inc., (514) 844-5558
ext 311, firstname.lastname@example.org